Stifel Nicolaus Increases Intrexon (XON) Price Target to $57.00

Intrexon (NYSE:XON) had its price target increased by Stifel Nicolaus from $39.00 to $57.00 in a report issued on Friday, November 10th, MarketBeat Ratings reports. Stifel Nicolaus currently has a buy rating on the biotechnology company’s stock.

Several other research analysts have also issued reports on XON. Zacks Investment Research lowered shares of Intrexon from a hold rating to a sell rating in a research note on Thursday, July 13th. BidaskClub lowered shares of Intrexon from a hold rating to a sell rating in a research note on Friday, August 4th. Northland Securities set a $30.00 price target on shares of Intrexon and gave the stock a buy rating in a research note on Monday, August 7th. JMP Securities reiterated an outperform rating and issued a $42.00 price target on shares of Intrexon in a research note on Thursday, October 5th. Finally, Griffin Securities reiterated a buy rating and issued a $55.00 price target on shares of Intrexon in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Intrexon presently has a consensus rating of Hold and a consensus price target of $38.50.

Shares of Intrexon (XON) traded up $0.60 during trading on Friday, hitting $13.54. 1,463,000 shares of the company traded hands, compared to its average volume of 1,140,025. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.05 and a quick ratio of 1.85. Intrexon has a 52 week low of $10.26 and a 52 week high of $30.96.

A number of large investors have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC bought a new stake in Intrexon during the 3rd quarter valued at about $121,000. GSA Capital Partners LLP bought a new stake in Intrexon during the 3rd quarter valued at about $1,945,000. Sheaff Brock Investment Advisors LLC increased its stake in Intrexon by 18.1% during the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 40,452 shares of the biotechnology company’s stock valued at $769,000 after purchasing an additional 6,210 shares in the last quarter. Wells Fargo & Company MN increased its stake in Intrexon by 13.8% during the 3rd quarter. Wells Fargo & Company MN now owns 118,462 shares of the biotechnology company’s stock valued at $2,252,000 after purchasing an additional 14,333 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Intrexon by 7,504.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 59,622 shares of the biotechnology company’s stock valued at $1,122,000 after purchasing an additional 58,838 shares in the last quarter. Institutional investors and hedge funds own 77.39% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/stifel-nicolaus-raises-intrexon-corporation-xon-price-target-to-57-00/1774417.html.

About Intrexon

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.